Welcome to our dedicated page for Promis Neuroscie SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProMIS Neurosciences Inc. (Nasdaq: PMN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, proxy statements and other key documents. ProMIS is a clinical-stage biotechnology company focused on antibody and vaccine candidates targeting toxic misfolded protein oligomers in neurodegenerative and other misfolded protein diseases, and its filings offer detailed insight into corporate actions, governance and clinical program updates.
Through recent Form 8-K filings, ProMIS has reported material events such as the implementation of a one-for-twenty-five reverse stock split of its common shares, effective November 28, 2025, and subsequent notification from Nasdaq that the company regained compliance with the $1.00 minimum bid price requirement. Other 8-Ks describe the recommendation of an independent Data and Safety Monitoring Board to advance the PRECISE-AD Phase 1b trial of PMN310 to the final dose escalation cohort, the establishment of an at-the-market offering program, and the appointment and compensation of directors and executives.
The company’s definitive proxy statement on Schedule 14A outlines matters submitted to shareholders, including authorization of the share consolidation and procedures for a virtual special meeting. These materials provide information on share structure proposals, voting results and corporate governance practices. Additional filings reference press releases reporting quarterly financial results, which are incorporated by reference into Item 2.02 of Form 8-K.
On Stock Titan, ProMIS filings are updated in line with EDGAR and can be reviewed alongside AI-powered summaries that explain the significance of each document. Investors can quickly see how reverse stock split mechanics, Nasdaq listing compliance, at-the-market offerings, and clinical trial milestones are described in official filings. Over time, this page will also aggregate annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 as they are filed, helping users track both the scientific and capital markets dimensions of PMN’s development.
ProMIS Neurosciences Inc. director Patrick D. Kirwin reported an open-market purchase of Common Shares through an associated professional corporation. The entity bought 4,000 shares at $11.33 per share, and now holds 4,653 shares indirectly. Kirwin also holds 5,135 shares directly and 305 shares indirectly through his spouse.
ProMIS Neurosciences Inc. is holding its 2026 annual shareholder meeting as a virtual-only webcast on May 20, 2026 at 10:30 a.m. Eastern Time, with a record date of March 23, 2026. Shareholders will elect seven directors, ratify Baker Tilly US, LLP as independent auditor, and vote on an amendment to the 2025 Stock Option and Incentive Plan.
The board is not nominating director Patrick Kirwin for re-election and is putting forward Dr. Slanix Alex as an independent nominee. As of March 23, 2026, 8,967,693 common shares were outstanding, with significant holders including entities affiliated with Janus Henderson at 14.99%. The proxy also details board independence, committee structures, director compensation and a non-employee director pay and option policy.
Janus Henderson Group plc reported beneficial ownership of 1,292,757 common shares of PROMIS Neurosciences Inc. The filing (Schedule 13G) states this represents 14.4% of the class as of 03/31/2026 with shared voting and dispositive power over those shares. The filing is signed on 04/07/2026.
ProMIS Neurosciences filed a shelf registration and prospectus supplement to offer up to $50,000,000 of common shares under an at-the-market sales agreement.
The registration statement also covers up to $200,000,000 of securities in aggregate. Sales under the Sales Agreement with H.C. Wainwright & Co. LLC may be made from time to time on Nasdaq or otherwise, and Wainwright may receive commissions up to 3.0% of gross sales. The prospectus supplement states the company may use net proceeds to advance clinical development of PMN310, for working capital and general corporate purposes. The offering is subject to market conditions and completion of sales; timing and amounts sold will be determined by market conditions and the Sales Agreement.
ProMIS Neurosciences Inc. files its annual report describing a broad pipeline of antibody and vaccine candidates for neurodegenerative and misfolded protein diseases. Its lead program, PMN310 for Alzheimer’s disease, targets toxic amyloid-beta oligomers without binding monomers or plaque.
The company has completed enrollment of 144 patients in its Phase 1b PRECISE-AD trial across 21 U.S. sites, dosing monthly at 5, 10 or 20 mg/kg or placebo over 12 months. PMN310 has shown a generally favorable safety profile to date and received FDA Fast Track designation.
Beyond Alzheimer’s, ProMIS highlights preclinical programs for TDP-43 in ALS (PMN267), alpha-synuclein in synucleinopathies (PMN442), additional ALS targets such as RACK1 and SOD1, and vaccine efforts against amyloid-beta, alpha-synuclein and TDP-43. The report also outlines a layered intellectual property strategy built on licensed University of British Columbia algorithms, disease-specific epitopes, and antibody composition-of-matter patents.
ProMIS Neurosciences Inc. reported a 2025 net loss of $39.7 million, driven mainly by higher research and development spending of $33.4 million as it advanced its PRECISE-AD Phase 1b Alzheimer’s trial, after posting net income of $2.8 million in 2024.
Cash was $6.1 million as of December 31, 2025, with total assets of $9.2 million and a shareholders’ deficit of $1.3 million, reflecting increased accrued liabilities. The company subsequently closed a financing of up to $175 million, including $75 million up front and additional proceeds tied to future warrant exercises, which it expects to fund operations through 2027.
The PRECISE-AD Phase 1b trial of lead antibody PMN310 in Alzheimer’s disease was fully enrolled with 144 patients in December 2025. Six-month assessments and a blinded interim analysis are expected in mid to early Q3 2026, with unblinded top-line data anticipated in early 2027. PMN310 has Fast Track designation from the U.S. Food and Drug Administration and has shown a favorable safety profile to date with no treatment-related serious adverse events reported.
ProMIS Neurosciences Inc. files a Form S-3 to register 13,830,592 Common Shares for resale by certain purchasers from a January 29, 2026 private placement.
The registration covers (i) 6,815,296 Common Shares sold in the private placement, (ii) 6,915,296 Common Shares issuable upon exercise of Common Share Warrants, and (iii) 100,000 Common Shares issuable upon exercise of Pre-Funded Warrants. The company will not receive proceeds from resale by the Selling Securityholders, though it will receive proceeds from any warrant exercises for cash.
ProMIS Neurosciences reports that Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. beneficially owns 895,877 shares of Common Stock, representing 9.99% of the outstanding common shares.
That 895,877 figure comprises 696,378 shares held directly and 199,499 shares issuable upon warrants; an issuance limitation on certain warrants prevents exercise that would result in ownership above 9.99%. The filing bases percentages on approximately 8,967,740 shares outstanding, reflecting a one-for-twenty-five reverse split effective November 28, 2025 and shares reported as issued as of February 3, 2026.